Physiological hydrostatic pressure protects endothelial monolayer integrity.
Endothelial monolayer integrity is required to maintain endothelial barrier functions and has found to be impaired in several disorders like inflammatory edema, allergic shock, or artherosclerosis. Under physiologic conditions in vivo, endothelial cells are exposed to mechanical forces such as hydrostatic pressure, shear stress, and cyclic stretch. However, insight into the effects of hydrostatic pressure on endothelial cell biology is very limited at present. Therefore, in this study, we tested the hypothesis that physiological hydrostatic pressure protects endothelial monolayer integrity in vitro. We investigated the protective efficacy of hydrostatic pressure in microvascular myocardial endothelial (MyEnd) cells and macrovascular pulmonary artery endothelial cells (PAECs) by the application of selected pharmacological agents known to alter monolayer integrity in the absence or presence of hydrostatic pressure. In both endothelial cell lines, extracellular Ca(2+) depletion by EGTA was followed by a loss of vascular-endothelial cadherin (VE-caherin) immunostaining at cell junctions. However, hydrostatic pressure (15 cmH(2)O) blocked this effect of EGTA. Similarly, cytochalasin D-induced actin depolymerization and intercellular gap formation and cell detachment in response to the Ca(2+)/calmodulin antagonist trifluperazine (TFP) as well as thrombin-induced cell dissociation were also reduced by hydrostatic pressure. Moreover, hydrostatic pressure significantly reduced the loss of VE-cadherin-mediated adhesion in response to EGTA, cytochalasin D, and TFP in MyEnd cells as determined by laser tweezer trapping using VE-cadherin-coated microbeads. In caveolin-1-deficient MyEnd cells, which lack caveolae, hydrostatic pressure did not protect monolayer integrity compromised by EGTA, indicating that caveolae-dependent mechanisms are involved in hydrostatic pressure sensing and signaling.
Müller-Marschhausen
K
K
Institute of Anatomy and Cell Biology, University of Würzburg, Würzburg, Germany.
Waschke
J
J
Drenckhahn
D
D
D000199:Actins / Q000378:metabolism; D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D015820:Cadherins / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D002199:Capillary Permeability / Q000187:drug effects; D021941:Caveolae / Q000502:physiology; D051242:Caveolin 1 / Q000235:genetics / Q000378:metabolism; D002448:Cell Adhesion; D002614:Chelating Agents / Q000494:pharmacology; D003331:Coronary Vessels / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D015638:Cytochalasin D / Q000494:pharmacology; D004533:Egtazic Acid / Q000494:pharmacology; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D006874:Hydrostatic Pressure; D051379:Mice; D018345:Mice, Knockout; D008833:Microcirculation / Q000502:physiology; D011651:Pulmonary Artery / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D013917:Thrombin / Q000378:metabolism; D014268:Trifluoperazine / Q000494:pharmacology; D000099152:Cadherin 5
D000199:Actins; D015703:Antigens, CD; D015820:Cadherins; D002118:Calcium; D051242:Caveolin 1; D002614:Chelating Agents; D015638:Cytochalasin D; D004533:Egtazic Acid; D013917:Thrombin; D014268:Trifluoperazine; D000099152:Cadherin 5; C495541:Cav1 protein, mouse